Drug Type Small molecule drug |
Synonyms AtorFen, Atorvastatin/fenofibrate, LCP-AtorFen |
Target |
Action inhibitors, agonists |
Mechanism HMG-CoA reductase inhibitors(HMG-CoA reductase inhibitors), PPARα agonists(Peroxisome proliferator-activated receptor α agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2/3 |
First Approval Date- |
Regulation- |
Molecular FormulaC66H76CaF2N4O13 |
InChIKeyHIZONJHAVINWOX-NIJVSVLQSA-N |
CAS Registry344423-98-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Dyslipidemias | Phase 3 | United States | 01 Oct 2007 |
Phase 2/3 | 140 | (LCP-AtorFen 40/100mg) | akmhioykuh(iqnyumpwjv) = dulshimzjw lfrtnjobgv (swcfqvarfv, 13.58) View more | - | 24 Mar 2020 | ||
Atorvastatin (Atorvastatin 40 mg) | akmhioykuh(iqnyumpwjv) = ijfidaslim lfrtnjobgv (swcfqvarfv, 18.18) View more | ||||||
Phase 2 | 220 | (LCP-AtorFen 40/100mg) | wahfqprjuz(negvgjursq) = xppsnaoqxf ypcmaicquh (bkwsyttwva, 16.2) View more | - | 05 Feb 2020 | ||
(Atorvastatin 40mg) | wahfqprjuz(negvgjursq) = hkjevbfcxt ypcmaicquh (bkwsyttwva, 17.3) View more |